MX2019004179A - Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer. - Google Patents
Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer.Info
- Publication number
- MX2019004179A MX2019004179A MX2019004179A MX2019004179A MX2019004179A MX 2019004179 A MX2019004179 A MX 2019004179A MX 2019004179 A MX2019004179 A MX 2019004179A MX 2019004179 A MX2019004179 A MX 2019004179A MX 2019004179 A MX2019004179 A MX 2019004179A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- disease
- alzheimer
- treatment
- same
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 229950002889 apilimod Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- HSKAZIJJKRAJAV-KOEQRZSOSA-N n-[(e)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine Chemical compound CC1=CC=CC(\C=N\NC=2N=C(OCCC=3N=CC=CC=3)N=C(C=2)N2CCOCC2)=C1 HSKAZIJJKRAJAV-KOEQRZSOSA-N 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662407186P | 2016-10-12 | 2016-10-12 | |
| PCT/US2017/056147 WO2018071548A1 (en) | 2016-10-12 | 2017-10-11 | Apilimod compositions and methods for using same in the treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019004179A true MX2019004179A (es) | 2019-09-02 |
Family
ID=60268450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019004179A MX2019004179A (es) | 2016-10-12 | 2017-10-11 | Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190365771A1 (enExample) |
| EP (1) | EP3525794A1 (enExample) |
| JP (1) | JP7199349B2 (enExample) |
| KR (1) | KR20190067824A (enExample) |
| CN (1) | CN110167559A (enExample) |
| AU (1) | AU2017342262B2 (enExample) |
| BR (1) | BR112019007214A2 (enExample) |
| CA (1) | CA3039199A1 (enExample) |
| IL (1) | IL265911A (enExample) |
| MX (1) | MX2019004179A (enExample) |
| RU (1) | RU2019113752A (enExample) |
| WO (1) | WO2018071548A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019164861A1 (en) | 2018-02-21 | 2019-08-29 | AI Therapeutics, Inc. | Combination therapy with apilimod and glutamatergic agents |
| CN112791078B (zh) | 2019-11-13 | 2022-12-06 | 润佳（苏州）医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途 |
| JP7744350B2 (ja) | 2020-01-13 | 2025-09-25 | バージ アナリティクス，インコーポレイテッド | 置換ピラゾロ－ピリミジンおよびその使用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7923557B2 (en) | 2004-11-10 | 2011-04-12 | Synta Pharmaceuticals Corporation | Process for preparing trisubstituted pyrimidine compounds |
| US7863270B2 (en) | 2005-05-13 | 2011-01-04 | Synta Pharmaceuticals Corp. | IL-12 modulatory compounds |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| EP2661445A2 (en) * | 2011-01-04 | 2013-11-13 | Universität Zürich | Modulators of il-12 and/or il-23 for the prevention or treatment of alzheimer's disease |
| JP6705828B2 (ja) * | 2014-11-07 | 2020-06-03 | エイアイ・セラピューティクス・インコーポレーテッド | 腎癌の処置に使用するためのアピリモド |
| PT3215157T (pt) * | 2014-11-07 | 2019-07-12 | Ai Therapeutics Inc | Apilimod para utilização no tratamento de melanoma |
| US10729694B2 (en) * | 2015-01-23 | 2020-08-04 | AI Therapeutics, Inc. | Anti-viral compositions containing PIKfyve inhibitors and use thereof |
| WO2016126707A1 (en) * | 2015-02-03 | 2016-08-11 | Lam Therapeutics, Inc. | Apilimod compositions and methods for using same |
| US10758545B2 (en) * | 2015-06-25 | 2020-09-01 | University Of Southern California | Methods to treat neurological diseases |
-
2017
- 2017-10-11 CN CN201780076520.2A patent/CN110167559A/zh active Pending
- 2017-10-11 US US16/340,845 patent/US20190365771A1/en not_active Abandoned
- 2017-10-11 JP JP2019519652A patent/JP7199349B2/ja active Active
- 2017-10-11 CA CA3039199A patent/CA3039199A1/en active Pending
- 2017-10-11 RU RU2019113752A patent/RU2019113752A/ru not_active Application Discontinuation
- 2017-10-11 MX MX2019004179A patent/MX2019004179A/es unknown
- 2017-10-11 EP EP17794818.9A patent/EP3525794A1/en not_active Withdrawn
- 2017-10-11 AU AU2017342262A patent/AU2017342262B2/en not_active Ceased
- 2017-10-11 BR BR112019007214A patent/BR112019007214A2/pt not_active Application Discontinuation
- 2017-10-11 WO PCT/US2017/056147 patent/WO2018071548A1/en not_active Ceased
- 2017-10-11 KR KR1020197012287A patent/KR20190067824A/ko not_active Ceased
-
2019
- 2019-04-08 IL IL265911A patent/IL265911A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018071548A1 (en) | 2018-04-19 |
| RU2019113752A (ru) | 2020-11-13 |
| BR112019007214A2 (pt) | 2019-07-02 |
| AU2017342262B2 (en) | 2023-09-28 |
| EP3525794A1 (en) | 2019-08-21 |
| KR20190067824A (ko) | 2019-06-17 |
| US20190365771A1 (en) | 2019-12-05 |
| CN110167559A (zh) | 2019-08-23 |
| AU2017342262A1 (en) | 2019-04-18 |
| JP7199349B2 (ja) | 2023-01-05 |
| RU2019113752A3 (enExample) | 2021-01-19 |
| IL265911A (en) | 2019-06-30 |
| CA3039199A1 (en) | 2018-04-19 |
| JP2019530711A (ja) | 2019-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA519400950B1 (ar) | Masp-3 تركيبات وطرق لتثبيط لعلاج أمراض واضطرابات مختلفة | |
| WO2018112365A3 (en) | Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii | |
| TW201613636A (en) | Methods of treating Alzheimer's Disease | |
| WO2019173795A3 (en) | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease | |
| PH12018500659A1 (en) | Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof | |
| MX377593B (es) | Composiciones para usar en el tratamiento de cáncer renal. | |
| EP4289820A3 (en) | Compounds for use in treating alzheimer's disease in apoe4+/+ patients | |
| MX2023010501A (es) | Profarmacos de dantroleno y metodos de su uso. | |
| PH12018501443A1 (en) | Methods of administering hepcidin | |
| MX2017006026A (es) | Apilimod para uso en el tratamiento de cancer colorrectal. | |
| MX2018011875A (es) | Reprogramacion cardiaca directa mejorada. | |
| EA201991175A1 (ru) | Применение в медицине интерферона-лямбда для лечения фиброза | |
| MX2019000677A (es) | Células miméticas de células b. | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
| MX2019004179A (es) | Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer. | |
| PH12016501658A1 (en) | Sialylated glycoprotein compositions and uses thereof | |
| MX383947B (es) | Composiciones de colágeno 7 y métodos para usar las mismas. | |
| PH12017501694A1 (en) | Compositions for the treatment of fibrosis and fibrosis-related diseases | |
| PH12019501358A1 (en) | Methods of administering hepcidin | |
| MX2019009293A (es) | Compuestos, composiciones y usos de los mismos para la mejoria de trastornos oseos. | |
| EP3634979A4 (en) | COMPOSITIONS AND METHODS OF TREATING ALZHEIMER'S MORBUS | |
| GEP20207145B (en) | Combination of trazodone and gabapentin for the treatmen | |
| PH12017501693A1 (en) | Compositions for the treatment of kidney and/or liver diseases | |
| HK40013419A (en) | Apilimod compositions and methods for using same in the treatment of alzheimer's disease | |
| MA39718A (fr) | Compositions et méthodes d'utilisation de celles-ci |